Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Alemtuzumab for multiple sclerosis

Willis, Mark ORCID: and Robertson, Neil ORCID: 2016. Alemtuzumab for multiple sclerosis. Current Neurology and Neuroscience Reports 16 , 84. 10.1007/s11910-016-0685-y

[thumbnail of art%3A10.1007%2Fs11910-016-0685-y.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (741kB) | Preview


Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials have demonstrated a dramatic effect on relapse rates as well as a positive effect on radiological disease outcomes and disability measures. Despite a mechanism of action that results in profound lymphopaenia, opportunistic infections are rarely seen and no excess association with malignancy has been identified. However, acquired autoimmune disease (AID) is a common adverse event following treatment, necessitating rigorous monitoring in order to facilitate prompt detection and management. Despite this issue, a unique dosing schedule and durability of effect make alemtuzumab a welcome addition to currently available treatment options for MS.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects: R Medicine > R Medicine (General)
Additional Information: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
Publisher: SpringerLink
ISSN: 1528-4042
Date of First Compliant Deposit: 10 November 2016
Date of Acceptance: 1 August 2016
Last Modified: 12 May 2023 12:39

Citation Data

Cited 32 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics